MICROTECH MED-B (02235) released its interim results, with a net profit attributable to the parent company of 40.2732 million yuan, turning a profit compared to the same period last year.

MICROTECH MED-B (02235) announced its mid-year results for 2026, with operating revenue of 414 million yuan, a year-on-year increase of 68.4%; gross profit of 239 million yuan, a year-on-year increase of 88.1%; profit attributable to the parent company of 40.2732 million yuan, turning a profit compared to the previous year; and earnings per share of 0.1 yuan. The announcement stated that the significant increase in revenue is mainly attributed to the rapid growth in domestic and international sales of continuous glucose monitoring systems, as well as a notable increase in international market sales of insulin pump systems. Net profit turned from loss to profit, primarily due to the substantial rise in operating revenue, significant expansion in gross profit margin, and ongoing optimization of expense ratios.